尿路基因制药 URGN
$24.75 −$0.98 (-3.81%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $24.00 -3.03%
开盘$25.83
昨收$25.73
当日区间$24.40 – $26.34
成交量1.76M
市值$1.21B
市盈率（TTM）–
股息率–
URGN 相关新闻
匹配 UroGen Pharma Ltd 或代码 URGN 的头条新闻，按最新排序。
- A Quick Look at Today's Ratings for UroGen Pharma Ltd(URGN.US), With a Forecast Between $48 to $75
- Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $60 正面
- H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $75
- Guggenheim Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $42 正面
- TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $50 正面
- Goldman Sachs Maintains UroGen Pharma Ltd(URGN.US) With Hold Rating, Raises Target Price to $44 正面
- Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $50 正面
- H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $45
- TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $35
- Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $40 正面
- Urogen Pharma (URGN) Receives a Buy From H.C. Wainwright
- Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $40
- Ladenburg Thalmann Initiates UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $43
- H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $45 正面
- H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $40
暂无评论——快来第一个聊聊 URGN。
登录后参与讨论。